

RESEARCH AND INNOVATION ARE THE KEY TO STAY AT THE FOREFRONT OF ANY EMERGING INDUSTRY

What are some significant innovations taking place in your respective field(s)?

Which among these is the most exciting and why? How will it (or they, if more than one) impact your organization?

Research and Innovation are the key to stay at the forefront of any emerging industry and that's what we at Meteoric do, we constantly research and innovate our products to suit the market demands worldwide. Classic example of our innovation was foraying into formulations in the year 2018 and now we have developed over 100 formulations to cater to different segments like Women and Men health, Kids and Adolescents health, Geriatrics as well as Gut Health.

These innovations in the formulations area will help us reach to the end consumer and know the consumer sentiment which we had not experienced being a B2B organization, above all it will help us leap faster into the area of unique and novel formulations.

Are you planning any new launches or are looking to open up new markets?

Yes we are continuously working towards introducing products as per customer requirements in newer markets, worldwide. We developed and launched various immunomodulators, supplements and provided end-to-end solutions with extremely short turnaround timelines during the COVID times.

Some key learnings from the COVID-19 fallouts for the industry have been the importance of ensuring accessibility of medicines and formulations and reducing over and repetitive import dependency. From a company angle, we plan to focus

GAURAV KAUSHIK

MD & CEO

Meteoric Biopharmaceuticals Pvt. Ltd.



on developing a more customized range of health supplements, immune functions products and increasing awareness of biological products and We formulate unique formulations and provide services of product customization and concept formulation to our customers. Each product is backed by clinically proven well researched ingredients

We boast promoting biological solutions vs synthetic products in human as well as veterinary pharma process.

In 2022 our focus will be on expanding the production capability and yield of this particular strain of probiotics. We plan to produce and commercialize this specialty probiotic recently isolated and characterized by us. We plan to launch specialty probiotic and prebiotic – certain classic synbiotics. We are actively working on a certain vegan alternative of animal-originated enzymes, and will be launching a few of them.

In terms of infrastructure investment, we are building an advanced fermentation facility to scale up potential Probiotics, their culture, certain Vitamins in Bioavailable form, and a few nutraceuticals imported in bulk from China. We will also include and expand more immunomodulator formulations.

Can cooperation with AYUSH lead to synergies for you? If so how?

A Memorandum of Understanding (MoU) was signed between Ministry of Ayush and Department of Biotechnology, Government of India with an aim to facilitate Inter-Ministerial Cooperation for evidence based biotechnological interventions in Ayush sector (May 2022)

The collaboration between traditional healthcare and biotechnology is expected to enable tremendous possibilities to undertake innovative and path-breaking research, which can be used for the exploration of various fundamental principles of Ayush systems. It is believed that Biotechnological R&D and Ayush Interventions would improve quality of life and life span (Vayahsthaapana Rasayana), as well as bring down the associated morbidity pertaining to chronic diseases such as diabetes, obesity, cardiovascular disease, osteoarthritis, cachexia, pain management and infectious diseases for example tuberculosis.

According to World Health Organization (WHO), 80% of the world population relies on herbal medicines for their primary health care and 45% world natural medicines are from plant origin. Therefore, exploring these synergies with this increasing demand of phytoextracts in natural product chemistry we are targeting the extraction of active metabolites in the form of purified herbal extracts to provide you the next door “one stop” solution with all kinds of herbal requirements along with the requisite technical support.

In case you have taken up any charitable activities / social work / any such initiative do tell us about these.

Along with our passion to grow we believe in deeper responsibility towards the society and hence we are working actively with our CSR partner VISHALWIN FOUNDATION. The foundation works with children and young adults with Down Syndrome, Autism, Global Developmental Delay and similar issues. Under the RENU Programme (Rehabilitation and Empowerment of Needy and Underprivileged) the foundation reaches out to children with special needs in the economically weaker section and identifies their early intervention needs by conducting medical camps in urban rurals. These children are checked by paediatric neurologists, psychotherapist, and physiotherapists during the camp and later given admission to an early intervention centre where their IEP (Individual Education Plan) is developed and their regular therapies like speech therapy, occupational therapy and physiotherapy is planned and executed. The goal is to make these children school ready.

Any thoughts on the role that Government can play – any tips / suggestions / view points that may be shared?

There is a need to organize the framework for incentive model into biopharma sector. The R & D costs for biopharma companies are exorbitant, support schemes incentivizing the R & D costs are sort from the government.

SME's are major contributors into employment generation hence there has to be equal opportunities for SME's. PLI schemes offered to the pharma sector are concentrated to larger brands and not companies dealing into biological API's, ingredients which is the need of the hour, this scheme needs extent support to manufacturers of API's, ingredients especially into biologicals.

Due to abrupt & extremely high freight charges as well as unavailability of containers & cargos SME's are facing great challenge in export drive. This should be regulated (semi or completely) to increase profitability & increase export potential in which SME's are top contributors.



The collaboration between traditional healthcare and biotechnology is expected to enable tremendous possibilities to undertake innovative and path-breaking research, which can be used for the exploration of various fundamental principles of Ayush systems.

